Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma

BACKGROUND: Robust ERK1/2 activity, which frequently results from KRAS mutation, invariably occurs in pancreatic ductal adenocarcinoma (PDAC). However, direct interference of KRAS signaling has not led to clinically successful drugs. Correct localization of RAF is regulated by the scaffold protein p...

Descripción completa

Detalles Bibliográficos
Autores principales: Luan, Zhou, He, Ying, Alattar, Mohamed, Chen, Zhishui, He, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938031/
https://www.ncbi.nlm.nih.gov/pubmed/24568222
http://dx.doi.org/10.1186/1476-4598-13-38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938031/
https://www.ncbi.nlm.nih.gov/pubmed/24568222
http://dx.doi.org/10.1186/1476-4598-13-38

Ejemplares similares